As we follow the journey of various neoantigen and neoepitope approaches from start-up and preclinical research through to the clinic, it’s been interesting to see how different companies and academic research groups have chosen to consider their R&D strategies.
Some of the companies we’ve interviewed and highlighted in this space include Neon Therapeutics, BioNTech, Gritstone, and newcomer, Achilles Therapeutics, along with various academic programs such as George Coukos’s neoepitope vaccine approach in Lausanne.
After we first spoke with Gritstone a couple of years ago, things seemed to go a bit quiet on the western front while Neon, BioNTech, and Achilles all had news to talk about. It’s always hard to choose from rock-paper-scissors and this may well be another modern twist of that genre until clinical data proves otherwise.
That all changed with more data being presented by the California-based biotech recently, plus patients are also being enrolled into their first neoantigen clinical trial.
At a recent conference, we caught up with their CMO, Dr Raphael Rousseau, to find out more about where they are and importantly, where they’re headed…
To learn more from our latest conference coverage and oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
Times Square, New York
New York – Every now and then you go to a cancer conference and instead of hearing the expected standard talk that is repeated time and time again for a season or so, you are delighted with a more engaging and uninhibited approach that captivates and informs on the latest state of the art progress.
It also means that more than the presenter realises is perhaps shared. That’s very good news indeed for intrepid science writers and anyone who cares to listen or read.
The research mentioned in today’s post falls in the engaged and delighted category…
To learn more from our latest assessment and get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
La Tour Eiffel par nuit
Paris, France: It’s the dog days of summer and my reading stack of interesting science and cancer research papers is particularly high at the moment despite reading voraciously over the last few weeks…
So much excellent research keeps on piling up as fast as one can get through it.
It’s beginning to feel like Ravel’s Bolero…
Still, there’s one particular batch of important papers that draws together some interesting findings in an area we have been following for a little while now and these data most certainly advance the field in more ways than one.
Subscribers can log-in to read our latest insights or you can purchase access to BSB Premium Content.